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ABSTRACT

Disclosed herein are methods and materials for influencing
proliferation of stem cells. Specifically exemplified herein are
compositions comprising cerium oxide nanoparticles which
can be used to stimulate proliferation of stem cells under
common culture conditions, or which can be utilized to
improve therapeutic outcomes.
2 Claims, No Drawings
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METHODS AND MATERIALS FOR
STIMULATING PROLIFERATION OF STEM
CELLS

cavity fluidly connected to a target tissue. In certain preferred
embodiments, the body cavity is a brain ventricle. In other
embodiments, the stem cells are inserted using a syringe or
catheter, or surgically implanted directly at the target tissue
site. In other embodiments, the stem cells are administered
parenterally. Parenteral administration is historically defined
as administration via a route that bypasses the gastrointestinal
tract. Therefore, technically parenteral administration
includes intraventricular administration, but intraventricular
administration is typically discussed herein as separate from
other modes of administration that may fall under 'parenteral
administration'.
The compositions can be administered alone or in combination with at least one other agent, such as stabilizing or
buffer compounds, which can be administered in any sterile,
biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. In addition
to the critical components of compositions discussed herein,
cells or influencing factors, the compositions can contain
suitable pharmaceutically acceptable carriers comprising
excipients and auxiliaries which facilitate processing of the
active compounds into preparations which can be used pharmaceutically. Generally compositions can be administered by
any number of routes including, but not limited to, oral,
intravenous, intramuscular, intra-arterial, intramedullary,
intrathecal, intraventricular, transdermal, subcutaneous,
intraperitoneal, intranasal, parenteral, topical, sublingual, or
rectal means. Factors can be administered at the same location as administered stem cells. Administration of influencing
factors and stem cells can be conducted simultaneously, or
one prior to the other, and at the same or different locations so
long as the relative locations allow for the factors to influence
the stem cells.
The administration of cerium oxide nanoparticles to stem
cells can be conducted in vivo, ex vivo, in situ, and/or in vitro.
According to a specific embodiment, cerium oxide nanoparticles are applied to stem cells in vitro. This will aid and
facilitate basic experiments conducted on stem cells that will
benefit from stimulation of the stem cells or to create for the
stem cells an environment where oxidants are minimized. In
other embodiments, the invention is directed to the stem cell
proliferating cerium oxide nanoparticle compositions themselves.
In other embodiments, the environment of administered
stem cells is modified by administration of a separate population of stem cells that are engineered to express influencing
factors. Engineered stem cells designed to express influencing factors may be produced according to previously disclosed methods. See for example U.S. Patent Publication
Nos. 20060134789 and 20060110440. According to a specific method embodiment, a population of therapeutic stem
cells are administered to a locus of a subject's body and a
population of engineered stem cells is administered at or
proximate to the therapeutic population. Influencing factors
are expressed and released from the engineered stem cells
which in tum influence the therapeutic stem cells for a desired
objective.
Thus, the invention also provides improved methods of
treating health conditions implementing a stem cell strategy.
For example, the methods taught herein may be used to treat
or ameliorate symptoms due to a corporal or neurological
(affecting nervous system), such as a deficit caused by a
neurodegenerative disease, a traumatic injury, a neurotoxic
injury, ischemia, a developmental disorder, a disorder affecting vision, an injury or disease of the spinal cord, a demyelinating disease, an autoimmune disease, an infection, an
inflammatory disease, or corporal disease, disorder, injury,

RELATED APPLICATIONS
This is a division of U.S. Ser. No. 11/968,393, filed Jan. 2,
2008 now abandoned, and also claims priority to U.S. Ser. No.
60/883,081, filed Jan. 2, 2007, which is incorporated herein
by reference in its entirely.
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BACKGROUND OF THE INVENTION
Patients currently suffering from neurodegenerative conditions such as Alzheimer's and Parkinson's have limited
treatment options. Conventional drug therapy helps delay or
reduce the symptoms of disease but is unable to restore complete functionality of the brain or repair damaged tissue.
Through stem cell-based therapies, scientists aim to transplant cells in order to regenerate damaged tissue and restore
proper function. In addition to addressing neurodegenerative
diseases, stem cell based therapies show much promise in
addressing a vast number of other diseases, injuries and conditions. The discovery of safe and inexpensive compositions
to modulate stem cell proliferation would be a beneficial
advancement in the filed of stem cell-based therapies and
basic research.
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DETAILED DESCRIPTION
30

Scientists are beginning to realize the potential power of
stem-cell based therapies. It is widely recognized that stem
cell transplantation may lead to treatments and/or cures of
baneful disease states, degeneration and/or injury. The ability
to stimulate the proliferation of stem cells in vivo or in vitro
will be of tremendous benefit. The subject invention is based
on the inventors discovery that certain nanoparticles can
affect the proliferation of stem cells.
In one embodiment, the subject invention pertains to a
method of improving therapeutic outcomes of implanted
stem cells comprising administering a Cerium Oxide (Ce0 2 )
nanoparticle composition in conjunction with stem cell
implantation. The administration of the Cerium Oxide composition can be at or proximate to a target stem cell implantation site in a human or nonhuman animal. In an alternative
embodiment, the environment may be further modified by
provision of influencing factors or by cleaning the environment of undesired or toxic agents that may affect administered stem cells in an undesired way. The administered stem
cells may be unmodified or may themselves be engineered to
be biased toward a target differentiation endpoint. U.S. Patent
Publication Nos. 20060134789 and 20060110440 are incorporated by reference to provide examples of stem cells engineered for negative and positive differentiation biasing that
are contemplated for use with the methods taught herein.
In another embodiment, the subject invention involves the
administration of a composition comprising a administering
Cerium Oxide nanoparticle composition to a body and
administering stem cells to said body. The composition is
administered at a locus in said body so as to allow contact with
the stem cells. This may be at the same location, proximate to
the location or distal to the location of where stem cells are
administered.
Stem cells may be administered by injecting one or a plurality of stem cells with a syringe, inserting the stem cells with
a catheter or surgically implanting the stem cells. In certain
embodiments, the stem cells are administered into a body
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trauma, malfunction, degeneration or loss. See, for example,
U.S. Patent Publication No. 20030139410. In preferred
embodiments, implanted stem cells are capable of proliferating, migrating to an area of tissue damage, and/or differentiating in a tissue-specific manner and functioning in a manner
that reduces the neurological or corporal deficit. Stem cells
may be administered by injection with a syringe, inserting
cells with a catheter or surgically implanting cells. In certain
embodiments, stem cells are injected with a syringe into a
body cavity that is fluidly-connected to the area of neurological or corporal deficit. In certain preferred embodiments, the
body cavity is a brain ventricle. In other embodiments, stem
cells are inserted with a catheter into a body cavity that is
fluidly-connected to the area of neurological or corporal deficit. In certain preferred embodiments, the body cavity is a
brain ventricle. In still further additional embodiments, stem
cells are surgically implanted into a body cavity that is fluidly-connected to the area of neurological or corporal deficit.
In certain preferred embodiments, the body cavity is a brain
ventricle. Stem cells can also alternatively be inserted using a
syringe or catheter or surgically implanted directly at the site
of the neurological or corporal deficit or systemically (e.g.,
intravenously).
The invention provides methods of delivery and transplantation of stem cells to ameliorate the effects of age, physical
and biological trauma and degenerative disease on the brain
or central nervous system of a human or nonhuman animal, as
well as other tissues such as, for example, retinal tissue. It is
well recognized in the art that transplantation of tissue into the
CNS offers the potential for treatment of neurodegenerative
disorders and CNS damage due to injury. Transplantation of
new cells into the damaged CNS has the potential to repair
damaged circuitries and provide neurotransmitters thereby
restoring neurological function. It is also recognized in the art
that transplantation into other tissue, such as eye tissue, offers
the potential for treatment of degenerative disorders and tissue damage due to injury. As disclosed herein, the invention
provides methods for methods of modifying a tissue environment to influence proliferation, migration and differentiation
of administered stem cells when introduced into a target site.
In a certain specific embodiments, target sites may be those
appropriate for treatment of neurological disorders and CNS
damage.
Recipients of administered stem cells can be immunosuppressed, either through the use of immunosuppressive drugs
such as cyclosporin, or through local immunosuppression
strategies employing locally applied immunosuppressants,
but such immunosuppression need not necessarily be a prerequisite in certain immunoprivileged tissues such as, for
example, brain and eye tissues. In certain embodiments, the
delivery method of the invention can cause less localized
tissue damage to the site of cell damage or malfunction than
existing methods of delivery.
In certain embodiments, administered stem cells are
autologous in nature, i.e., prepared from the recipient's own
tissue. In such instances, the progeny of stem cells can be
generated from dissociated or isolated tissue and proliferated
in vitro using known methods. In the case of mesenchymal
stem cells (MeSCs), progeny can be generated from MeSCs
isolated from, for example, bone marrow. Upon suitable
expansion of cell numbers, the stem cells of the invention can
be harvested and readied for administration into the recipient's affected tissue.
Reference to particular buffers, media, reagents, cells, culture conditions and the like, or to some subclass of same, is
not intended to be limiting, but should be read to include all
such related materials that one of ordinary skill in the art

would recognize as being of interest or value in the particular
context in which that discussion is presented. For example, it
is often possible to substitute one buffer system or culture
medium for another, such that a different but known way is
used to achieve the same goals as those to which the use of a
suggested method, material or composition is directed.
It is important to an understanding of the present invention
to note that all technical and scientific terms used herein,
unless defined herein, are intended to have the same meaning
as commonly understood by one of ordinary skill in the art.
The techniques employed herein are also those that are known
to one of ordinary skill in the art, unless stated otherwise. For
purposes of more clearly facilitating an understanding the
invention as disclosed and claimed herein, the following definitions are provided.

10

15

EXAMPLE 1
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Preparation of Cerium Oxide Nanoparticles
Cerium oxide nanoparticles of a size approximately 2 nm
to approximately 10 nm in diameter, are prepared by a process
including the steps of dissolving approximately 0.5 grams to
approximately 1.0 grams of Ce(N0 3 ) 3 .6H 2 0 in deionized
water to make approximately 10 mis of solution to form a first
solution, followed by dissolving approximately 3 grams to
approximately 4 grams of AOT (surfactant) in approximately
200 ml of solvent to form a second solution, followed by
combining the first and the second solutions, followed by
stirring the combined solutions for approximately 30 minutes, and drop wise adding approximately 30% hydrogen
peroxide (H 2 0 2 ) until the stirred combined solution becomes
yellow, and subsequently stirring for approximately 30 minutes to approximately 60 minutes more. Thus, aqueous
reverse micelles (RMs) are surfactant aggregates in nonpolar
solvents that enclose packets of aqueous solution in their
interior. The size of the water droplet can be tuned by varying
the ratio of water to surfactant. RMs used as reaction media in
the production of nanoparticles whose size and shape are
controlled by water and surfactant ratio. The surfactant is
stripped off using simple washing and drying. Size: 3-5 nm.
EXAMPLE2
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The synthesis of ceria was carried out by direct synthesis
route from the cerium precursor (Ce(N0 3 ) 3 .6H 2 0) dissolved
in water. Oxidation of cerium nitrate was carried out using
hydrogen peroxide (H 2 0 2 ). It is a very simple one step process yielding ceria nanoparticles dispersed in water (a very
useful delivery media for biological studies). The process
leads to formation of cerium oxide nanoparticles of 15-20 nm
particle size (agglomerates) consisting 3-5 nm spherical crystals.

55

EXAMPLE3
Particles may be obtained via heating of the particles in
produced in Example 1 above, anywhere between 100-400 C.
60

EXAMPLE4
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Cerium oxide particles are obtained from commercially
available sources. Particles are dried from the slurry, washed
in water and redispersed in the water at a certain pH. Without
being bound to any particular theory, it is believed that the
variation in the stem cell proliferation, though not yet shown
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to be statistically significant, appears to be attributable to
difference in the Ce+3/Ce+4 ratio in the samples.

of cell proliferation had a marked increase. Though all
samples showed an influence on proliferation, Sample 3,
which is composed ofCe02 nanoparticles 10-20 nm in size
and spherically shaped and showed highest increase,
increased mesenchymal stem cell proliferation rates by as
much as 50%.
While a number of embodiments of the present invention
have been shown and described herein in the present context,
such embodiments are provided by way of example only, and
not of limitation. Numerous variations, changes and substitutions will occur to those of skilled in the art without materially departing from the invention herein. It should be borne
in mind that all patents, patent applications, patent publications, technical publications, scientific publications, and
other references referenced herein are hereby incorporated by
reference in this application, in their entirety to the extent not
inconsistent with the teachings herein.

EXAMPLES
Stimulation of Stem Cell Proliferation
Stem cell growth and division rates can be increased by
lowering the oxidative stress on the cells. We propose using
this method to increase the proliferation rates of stem cells
under common culture conditions. Specifically, we can
improve stem cell proliferation rates by as much as 50%.
Furthermore, we propose that this method can be used to
enable the growth of stem cells for emergency tissue repair as
well as for therapeutic use. This therapy can be used in conjunction with currently available drugs and biologics with
little concern over negative interactions and helps eliminate
the possibility for graft-verse-host disease. Using five different samples of cerium oxide, Ce02, nanoparticles, size and
shape, 3-5 nm spherical, 11-15 nm agglomerates of 3-5 nm
individual crystals, 10-20 nm spherical, 7-10 nm spherical,
and 10-20 nm cuboidal, the inventors found a good working
concentration by making serial dilutions of each sample, then
applied each for a plated dish of rat mesenchymal stem cells,
also known as adult stem cells. Although a wide range of
concentrations can be used, the inventors found that 10 nM
appeared to be an optimal concentration. When rat and human
mesenchymal stem cells were plated at known densities,
treated with one of the Ce02 samples, allowed to grow for
periods of 24, 48, and 72 hours, then performed a cell count
for each of the samples and the control untreated cells, the rate
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What is claimed is:
1. A method of stimulating proliferation of a population of
stem cells, said method comprising contacting said population with cerium oxide nanoparticles in vitro, wherein said
nanoparticles are spherical in shape and are about 10-20 nm in
size and are provided in a culture media at a concentration to
promote proliferation of said stem cells; and
culturing said population of stem cells in said culture
media under conditions and time period to increase the
population of stem cells.
2. The method of claim 1, wherein said stem cells are
mesenchymal stem cells.
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